Fosun Pharma expands global reach and strengthens operations

Fosun Pharma’s semi-annual report for 2025 highlights a strategic licensing agreement with Sitala Bio Ltd., granting Sitala exclusive global rights (excluding China, Hong Kong, Macau, and Taiwan) for the development, production, and commercialization of FXS6837, a proprietary small molecule inhibitor for immunomodulatory and autoimmune diseases. This deal includes up to $190m in upfront, development, and commercial milestone payments, plus up to $48m in sales milestones, and an equity stake for Fosun Pharma worth $5m in Sitala. The company is also continuing its R&D into other innovative drugs, with a cumulative investment of RMB3.03m for FXS6837 by July 2025.

In parallel, Fosun Pharma renewed its financial services agreement with Fosun Hitech Financial Co. Ltd. (Fosun Financial Services) until December 31, 2028, maintaining credit lines up to RMB2bn and daily deposit limits up to RMB2bn. Additionally, a product/service supply framework agreement with Sinopharm Holdings was extended for the same period. These agreements are crucial for enhancing operational efficiency, controlling financing costs, and managing liquidity.

The company's reported total assets as of June 30, 2025, were RMB118.83bn, with a net profit of RMB1.70bn attributable to shareholders. This financial performance was partly driven by the divestment of remaining stakes in Unicorn II Holdings Limited, which operates the "United Family" hospitals and clinics. These initiatives underscore Fosun Pharma’s commitment to expanding its international presence while optimizing its financial and operational frameworks.